Article " Gilead Keeps LEAD in Hep C Race" /// post.
Gilead keeps lead in hep C race
April 25, 2013 | By Ryan McBride
After delivering data from multiple rounds of trials on all-oral combos against hepatitis C, pharma runners appear to be making progress with new therapies that could shorten treatment durations and wipe out the liver-damaging virus without infusions of interferon and the flu like side effects that go with them. However, nobody has managed to overtake Gilead Sciences ($GILD) as the frontrunner in the hep C race.